Trial Profile
A study of ABO-202 for patients with infantile neuronal ceroid lipofuscinosis
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 19 May 2021
Price :
$35
*
At a glance
- Drugs ABO 202 (Primary) ; ABO 202 (Primary)
- Indications Neuronal ceroid lipofuscinosis
- Focus Adverse reactions
- 11 May 2021 According to a Taysha Gene Therapies media release, the company expects to report biomarker data from the study in the first half of 2022.
- 14 Apr 2021 According to a Taysha Gene Therapies media release, dosing of first patient is expected in the second half of 2021.
- 03 Mar 2021 According to a Taysha Gene Therapies media release, the company expect to initiate this trial in the second half of 2021 with commercial-grade GMP material.